Odyssey insider reports 78,958-share stock option

Odyssey Therapeutics, Inc. insider Jolie Siegel reported existing derivative holdings on a Form 3.

Rhea-AI Filing Summary

Odyssey Therapeutics, Inc. insider Jolie Siegel reported existing derivative holdings on a Form 3. The filing shows a stock option to buy common stock with an exercise price of $5.15 per share for 78,958 underlying shares, expiring on March 11, 2036. According to the vesting terms, 25% of this option will vest on January 12, 2027, with the rest vesting in 36 equal monthly installments, contingent on continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Siegel Jolie

Role See Remarks

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 78,958 contracts (Direct)

Footnotes (1)

1. F1. 25% of the option will vest on January 12, 2027, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Underlying option shares: 78,958 shares Exercise price: $5.15 per share Expiration date: March 11, 2036 +2 more

5 metrics

Underlying option shares 78,958 shares Stock Option (Right to Buy) on common stock

Exercise price $5.15 per share Stock option strike price

Expiration date March 11, 2036 Option expiration

Initial vesting portion 25% Vests on January 12, 2027

Remaining vesting schedule 36 monthly installments After January 12, 2027, subject to continued service

Key Terms

Stock Option (Right to Buy), underlying security, exercise price, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

underlying security financial

"underlying_security_title: Common Stock"

exercise price financial

"conversion_or_exercise_price: 5.1500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"25% of the option will vest on January 12, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Odyssey Therapeutics (ODTX) Form 3 for Jolie Siegel report?

The Form 3 for Odyssey Therapeutics (ODTX) reports Jolie Siegel’s existing stock option holding. It covers an option to buy 78,958 shares of common stock at an exercise price of $5.15 per share, expiring on March 11, 2036.

How many Odyssey Therapeutics (ODTX) shares are covered by Siegel’s stock option?

Jolie Siegel’s reported stock option covers 78,958 underlying shares of Odyssey Therapeutics common stock. This is a right to buy shares in the future, not a current stock purchase or sale, and is reported as a derivative holding.

What is the exercise price of Jolie Siegel’s Odyssey Therapeutics (ODTX) option?

The exercise price of Jolie Siegel’s Odyssey Therapeutics stock option is $5.15 per share. This is the fixed price at which she may buy the underlying common shares once portions of the option vest under the disclosed schedule.

When does Jolie Siegel’s Odyssey Therapeutics (ODTX) option start vesting?

According to the filing footnote, 25% of Jolie Siegel’s option will vest on January 12, 2027. The remaining 75% then vests in 36 equal monthly installments, subject to her continued service with Odyssey Therapeutics on each vesting date.

Is the Odyssey Therapeutics (ODTX) Form 3 a stock purchase or sale by Jolie Siegel?

The Odyssey Therapeutics Form 3 does not show a stock purchase or sale by Jolie Siegel. It reports a stock option holding, giving her the right to buy 78,958 shares at $5.15 per share if and when the option vests and is exercised.

What is the expiration date of Jolie Siegel’s Odyssey Therapeutics (ODTX) stock option?

The reported stock option held by Jolie Siegel expires on March 11, 2036. After this expiration date, any unexercised portion of the option will lapse, meaning she would no longer be able to purchase shares under this particular grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/07/2026 - 09:31 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Siegel Jolie

(Last) (First) (Middle)

C/O ODYSSEY THERAPEUTICS, INC.

51 SLEEPER STREET, SUITE 800

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/07/2026

3. Issuer Name and Ticker or Trading Symbol
Odyssey Therapeutics, Inc. [ ODTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	03/11/2036	Common Stock	78,958	$5.15	D

Explanation of Responses:

1. 25% of the option will vest on January 12, 2027, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Executive Vice President, General Counsel and Secretary Exhibit 24 - Power of Attorney

	/s/ Jolie M. Siegel	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)